Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Phathom Pharmaceuticals Inc's Business Segments
Phathom Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable Segment Aggregation Before Other Operating Segment
Total Revenue
$ 58
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable Segment Aggregation Before Other Operating Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $ 58 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- VOQUEZNA Product100%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| VOQUEZNA Product | $ 58 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals Inc. is a biopharmaceutical company that focuses entirely on the development and commercialization of treatments for gastrointestinal diseases. The company was founded in 2018 and is headquartered in Buffalo Grove, Illinois. The company aims to improve the lives of patients suffering from gastrointestinal diseases, which are often challenging to diagnose and treat.
Phathom is driven by its mission to provide innovative treatments and medical solutions, which are based on deep scientific and clinical understanding of gastrointestinal diseases. The company's expertise is demonstrated by its current product portfolio, which includes two FDA-approved treatments for gastrointestinal diseases.
The first product, Omeprazole Magnesium-antazoline Sodium, is a combination therapy for the treatment of gastroesophageal reflux disease (GERD) and other acid-related conditions. This product is intended for patients who are unresponsive to conventional treatment options. The second product, Vonoprazan, is a proton pump inhibitor (PPI) that is used to treat GERD and for the prevention of gastric ulcers. Both products are highly effective and have helped many patients manage their symptoms and improve their quality of life.
In addition to its existing product portfolio, Phathom is also investing in the development of novel treatments for gastrointestinal diseases. The company has a deep pipeline of potential treatments that are currently in various stages of development, including treatments for Helicobacter pylori infection and eosinophilic esophagitis. The company's pipeline is highly promising, and many of its potential treatments have shown promising results in clinical trials.
Phathom has a highly experienced and skilled management team that is led by Dr. Azmi Nabulsi, who serves as the CEO. The company also has a strong group of investors, including leading venture capital firms and institutional investors. With its deep scientific understanding of gastrointestinal diseases, strong product portfolio, and promising pipeline, Phathom Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry for the treatment of gastrointestinal diseases.
Phathom is driven by its mission to provide innovative treatments and medical solutions, which are based on deep scientific and clinical understanding of gastrointestinal diseases. The company's expertise is demonstrated by its current product portfolio, which includes two FDA-approved treatments for gastrointestinal diseases.
The first product, Omeprazole Magnesium-antazoline Sodium, is a combination therapy for the treatment of gastroesophageal reflux disease (GERD) and other acid-related conditions. This product is intended for patients who are unresponsive to conventional treatment options. The second product, Vonoprazan, is a proton pump inhibitor (PPI) that is used to treat GERD and for the prevention of gastric ulcers. Both products are highly effective and have helped many patients manage their symptoms and improve their quality of life.
In addition to its existing product portfolio, Phathom is also investing in the development of novel treatments for gastrointestinal diseases. The company has a deep pipeline of potential treatments that are currently in various stages of development, including treatments for Helicobacter pylori infection and eosinophilic esophagitis. The company's pipeline is highly promising, and many of its potential treatments have shown promising results in clinical trials.
Phathom has a highly experienced and skilled management team that is led by Dr. Azmi Nabulsi, who serves as the CEO. The company also has a strong group of investors, including leading venture capital firms and institutional investors. With its deep scientific understanding of gastrointestinal diseases, strong product portfolio, and promising pipeline, Phathom Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry for the treatment of gastrointestinal diseases.
Phathom Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies specifically targeting gastrointestinal diseases. Its strategic focus is on creating effective, novel solutions that address unmet medical needs in this field. Below is an extensive overview of the companys segments, products, and services:
Segments
1. Esophageal Diseases
Phathom Pharmaceuticals is actively engaged in the development of therapeutic solutions for esophageal diseases, with a significant emphasis on gastroesophageal reflux disease (GERD). GERD is a chronic condition characterized by the backflow of stomach contents into the esophagus, which can result in symptoms such as heartburn and regurgitation. Phathom’s lead product candidate, PH-10, is under clinical trial for GERD and other acid-related disorders. This candidate represents a potential shift in the treatment paradigm for patients suffering from these conditions.
2. Gastric Diseases
The company also targets gastric diseases, which encompass a range of disorders such as Helicobacter pylori (H. pylori) infection, peptic ulcer disease, and gastric cancer. These conditions can lead to significant morbidity and require effective therapeutic interventions. Phathom’s efforts in this segment are geared towards developing treatment options that can not only alleviate symptoms but also address the underlying causes of these illnesses.
Products
Phathom Pharmaceuticals has developed a focused portfolio of products that include:
1. PH-10
- Description: PH-10 is a novel, highly potent and selective inhibitor of the proton pump, which plays a crucial role in gastric acid production.
- Indications: It is being investigated as an oral treatment option for GERD and other acid-related disorders. Its mechanism of action aims to provide effective and sustained relief from the symptoms of hyperacidity.
2. Vonoprazan
- Description: Vonoprazan is a cutting-edge proton pump inhibitor (PPI) that has shown substantial effectiveness in the inhibition of gastric acid secretion.
- Indications: This drug is under development for the treatment of conditions like H. pylori infection and peptic ulcer disease, as well as for other gastric disease management. It is notable for its rapid onset of action and long duration compared to traditional PPIs, potentially offering improved outcomes for patients.
Services
Phathom Pharmaceuticals provides a range of services designed to support healthcare professionals and patients, including:
1. Clinical Trials
- The company conducts rigorous clinical trials to evaluate the safety and efficacy of its pharmaceutical candidates. These trials are essential in understanding the therapeutic benefits and potential side effects of their products, ensuring that only safe and effective treatments reach the market.
2. Medical Education
- Phathom Pharmaceuticals invests in medical education initiatives aimed at enhancing the knowledge and skills of healthcare professionals. These programs focus on the latest advances in the diagnosis, management, and treatment of gastrointestinal diseases, ensuring that practitioners are equipped with up-to-date information and resources to provide optimal care.
3. Patient Support Programs
- Understanding the challenges faced by patients managing gastrointestinal disorders, Phathom Pharmaceuticals offers support programs designed to facilitate access to its medications and provide guidance for managing their conditions. These initiatives are aimed at helping patients navigate their treatment journeys and improving their overall quality of life.
Conclusion
In summary, Phathom Pharmaceuticals Inc. is deeply committed to enhancing the treatment landscape for gastrointestinal diseases through a specialized focus on innovative product development and comprehensive support services. Its segments encapsulate the breadth of gastrointestinal disorders affecting patients today, while its product candidates like PH-10 and Vonoprazan exemplify the company’s dedication to providing effective treatment options. Through its clinical trials, medical education, and patient support services, Phathom Pharmaceuticals is positioned to make a meaningful impact on the lives of patients dealing with these challenging health issues.
Segments
1. Esophageal Diseases
Phathom Pharmaceuticals is actively engaged in the development of therapeutic solutions for esophageal diseases, with a significant emphasis on gastroesophageal reflux disease (GERD). GERD is a chronic condition characterized by the backflow of stomach contents into the esophagus, which can result in symptoms such as heartburn and regurgitation. Phathom’s lead product candidate, PH-10, is under clinical trial for GERD and other acid-related disorders. This candidate represents a potential shift in the treatment paradigm for patients suffering from these conditions.
2. Gastric Diseases
The company also targets gastric diseases, which encompass a range of disorders such as Helicobacter pylori (H. pylori) infection, peptic ulcer disease, and gastric cancer. These conditions can lead to significant morbidity and require effective therapeutic interventions. Phathom’s efforts in this segment are geared towards developing treatment options that can not only alleviate symptoms but also address the underlying causes of these illnesses.
Products
Phathom Pharmaceuticals has developed a focused portfolio of products that include:
1. PH-10
- Description: PH-10 is a novel, highly potent and selective inhibitor of the proton pump, which plays a crucial role in gastric acid production.
- Indications: It is being investigated as an oral treatment option for GERD and other acid-related disorders. Its mechanism of action aims to provide effective and sustained relief from the symptoms of hyperacidity.
2. Vonoprazan
- Description: Vonoprazan is a cutting-edge proton pump inhibitor (PPI) that has shown substantial effectiveness in the inhibition of gastric acid secretion.
- Indications: This drug is under development for the treatment of conditions like H. pylori infection and peptic ulcer disease, as well as for other gastric disease management. It is notable for its rapid onset of action and long duration compared to traditional PPIs, potentially offering improved outcomes for patients.
Services
Phathom Pharmaceuticals provides a range of services designed to support healthcare professionals and patients, including:
1. Clinical Trials
- The company conducts rigorous clinical trials to evaluate the safety and efficacy of its pharmaceutical candidates. These trials are essential in understanding the therapeutic benefits and potential side effects of their products, ensuring that only safe and effective treatments reach the market.
2. Medical Education
- Phathom Pharmaceuticals invests in medical education initiatives aimed at enhancing the knowledge and skills of healthcare professionals. These programs focus on the latest advances in the diagnosis, management, and treatment of gastrointestinal diseases, ensuring that practitioners are equipped with up-to-date information and resources to provide optimal care.
3. Patient Support Programs
- Understanding the challenges faced by patients managing gastrointestinal disorders, Phathom Pharmaceuticals offers support programs designed to facilitate access to its medications and provide guidance for managing their conditions. These initiatives are aimed at helping patients navigate their treatment journeys and improving their overall quality of life.
Conclusion
In summary, Phathom Pharmaceuticals Inc. is deeply committed to enhancing the treatment landscape for gastrointestinal diseases through a specialized focus on innovative product development and comprehensive support services. Its segments encapsulate the breadth of gastrointestinal disorders affecting patients today, while its product candidates like PH-10 and Vonoprazan exemplify the company’s dedication to providing effective treatment options. Through its clinical trials, medical education, and patient support services, Phathom Pharmaceuticals is positioned to make a meaningful impact on the lives of patients dealing with these challenging health issues.